October 31st, 2014

Next
A full text version of this article is available.
To access article obtain online access here or login
 
Title:
Combination Therapy with Paclitaxel, Carboplatin and Megestrol Acetate for the Management of Advanced Stage or Recurrent Carcinoma of the Endometrium: A Phase II Study
Authors:  Kerri S. Bevis, M.D., Larry C. Kilgore, M.D., Ronald D. Alvarez, M.D., J. Michael Straughn, Jr., M.D., and Charles A. Leath, III, M.D.
  OBJECTIVE: To determine overall survival (OS), progression-free interval (PFI), and toxicity in patients with advanced stage or recurrent endometrial cancer (EMCA) treated with combination paclitaxel, carboplatin and megestrol acetate.

STUDY DESIGN: Patients with stage III/IV or recurrent EMCA were enrolled between October 2004 and April 2008 and received paclitaxel (175 mg/m2) and carboplatin (AUC 6) every 21 days for 6 cycles and megestrol acetate 40 mg orally 4 times daily for up to 5 years. Dose reductions were based on grade 3/4 hematologic toxicity. Survival was calculated from time of study enrollment.

RESULTS: A total of 28 patients were evaluable: 21 (75%) patients with stage III/IV disease and 7 (25%) with recurrent disease. Three patients with recurrence received prior radiation. Mean PFI was 40.2 months (29.750.6). Mean OS was 50.1 months (41.5 58.7). After a median 40.4 months (range, 5.668.4) of follow-up, 13 patients (46%) had no evidence of disease, 4 were alive with disease, and 10 were dead of disease. One patient died without evidence of disease. Twenty-three patients (82%) completed 6 cycles of chemotherapy. Ten patients experienced a dose reduction. Myelosuppression was common, with 22 patients (78%) experiencing grade 3/4 neutropenia and 6 patients (21%) experiencing grade 3/4 anemia. Three patients had a deep vein thrombosis. One patient experienced a pulmonary thromboembolus.

CONCLUSION: Combination therapy with paclitaxel, carboplatin and megestrol acetate demonstrates activity. Myelosuppression is common but can be managed with colony-stimulating factors. The addition of hormonal therapy to cytotoxic chemotherapy may improve survival.
Keywords:  carboplatin, chemotherapy, endometrial cancer, hormonal therapy, megestrol, paclitaxel, phase II trial
   
   
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from